Discussing the Supreme Court’s decision in Mayo v. Prometheus to reject two patents on a method for monitoring a patient’s blood to determine appropriate drug dosage as well as the decision’s potential to affect the profitability of personalized medicine, Partner Courtenay Brinckerhoff said the rejection is a disruption of the status quo that may result in less funding for research. First published in an article that appeared in Reuters, Ms. Brinckerhoff’s comments later appeared in additional publications including the Chicago Tribune, Yahoo! News, BioPortfolio and The Huffington Post.
People
Related News
December 3, 2025
In the News
Vanessa Miller Assesses Automotive Tariff Impact on Trucking Industry
Foley & Lardner LLP partner Vanessa Miller discussed the ongoing disruption in trucking demand resulting from recent automotive tariffs in the TruckingDive article, “Tariffs swing volumes up and down for auto haulers.”
November 28, 2025
In the News
Cassandra Aubert Assesses Circuit Split on SEC Disgorgement Authority
Foley & Lardner LLP associate Cassandra Aubert commented on the growing scrutiny around the U.S. Security and Exchange Commission's disgorgement authority in the Bloomberg Law's article, “SEC Power to Recoup Illegal Profits at Risk as Justices Eye Case."
November 25, 2025
In the News
Gregory Husisian Analyzes SCOTUS Tariff Case
Foley & Lardner LLP partner Gregory Husisian appeared in a SupplyChainBrain video interview to discuss the U.S. Supreme Court case on the Trump administration’s imposition of tariffs under the International Emergency Economic Powers Act (IEEPA) and options the administration can consider should the court strike them down.